Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $32,861 | 7 | 61.3% |
| Travel and Lodging | $19,190 | 20 | 35.8% |
| Food and Beverage | $1,599 | 32 | 3.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ViiV Healthcare Company | $31,362 | 27 | $0 (2020) |
| Merck Sharp & Dohme Corporation | $11,334 | 20 | $0 (2021) |
| Takeda Pharmaceuticals U.S.A., Inc. | $5,850 | 1 | $0 (2021) |
| GlaxoSmithKline, LLC. | $3,710 | 3 | $0 (2017) |
| Gilead Sciences, Inc. | $1,347 | 7 | $0 (2019) |
| Janssen Scientific Affairs, LLC | $47.52 | 1 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2021 | $7,550 | 2 | Takeda Pharmaceuticals U.S.A., Inc. ($5,850) |
| 2020 | $26,160 | 12 | ViiV Healthcare Company ($26,160) |
| 2019 | $11,848 | 34 | Merck Sharp & Dohme Corporation ($9,634) |
| 2017 | $8,092 | 11 | ViiV Healthcare Company ($4,335) |
All Payment Transactions
59 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 09/24/2021 | Takeda Pharmaceuticals U.S.A., Inc. | — | Consulting Fee | Cash or cash equivalent | $5,850.00 | General |
| 04/28/2021 | Merck Sharp & Dohme Corporation | — | Consulting Fee | Cash or cash equivalent | $1,700.00 | General |
| 07/28/2020 | ViiV Healthcare Company | — | Consulting Fee | Cash or cash equivalent | $7,194.97 | General |
| 04/06/2020 | ViiV Healthcare Company | — | Travel and Lodging | Cash or cash equivalent | $7,730.24 | General |
| 04/06/2020 | ViiV Healthcare Company | — | Consulting Fee | Cash or cash equivalent | $3,106.42 | General |
| 02/27/2020 | ViiV Healthcare Company | — | Travel and Lodging | In-kind items and services | $7,148.50 | General |
| 02/27/2020 | ViiV Healthcare Company | — | Travel and Lodging | In-kind items and services | $554.62 | General |
| 02/27/2020 | ViiV Healthcare Company | — | Food and Beverage | In-kind items and services | $95.99 | General |
| 02/27/2020 | ViiV Healthcare Company | — | Food and Beverage | In-kind items and services | $88.78 | General |
| 02/27/2020 | ViiV Healthcare Company | — | Food and Beverage | In-kind items and services | $86.14 | General |
| 02/27/2020 | ViiV Healthcare Company | — | Travel and Lodging | In-kind items and services | $60.23 | General |
| 02/27/2020 | ViiV Healthcare Company | — | Travel and Lodging | In-kind items and services | $42.15 | General |
| 02/27/2020 | ViiV Healthcare Company | — | Food and Beverage | In-kind items and services | $39.15 | General |
| 02/27/2020 | ViiV Healthcare Company | — | Food and Beverage | In-kind items and services | $12.78 | General |
| 10/24/2019 | ViiV Healthcare Company | — | Travel and Lodging | In-kind items and services | $354.23 | General |
| 10/24/2019 | ViiV Healthcare Company | — | Food and Beverage | In-kind items and services | $78.54 | General |
| 10/24/2019 | ViiV Healthcare Company | — | Travel and Lodging | In-kind items and services | $54.92 | General |
| 10/24/2019 | ViiV Healthcare Company | — | Food and Beverage | In-kind items and services | $34.80 | General |
| 10/15/2019 | Gilead Sciences, Inc. | Viread (Drug) | Food and Beverage | In-kind items and services | $85.24 | General |
| Category: HBV | ||||||
| 10/15/2019 | Gilead Sciences, Inc. | Viread (Drug) | Food and Beverage | In-kind items and services | $24.18 | General |
| Category: HBV | ||||||
| 09/13/2019 | Merck Sharp & Dohme Corporation | MK-8591 (Drug) | Food and Beverage | In-kind items and services | $54.79 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 09/13/2019 | Merck Sharp & Dohme Corporation | MK-8591 (Drug) | Food and Beverage | In-kind items and services | $52.18 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 09/13/2019 | Merck Sharp & Dohme Corporation | MK-8591 (Drug) | Food and Beverage | In-kind items and services | $44.35 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 09/12/2019 | Merck Sharp & Dohme Corporation | MK-8591 (Drug) | Travel and Lodging | In-kind items and services | $166.94 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 09/12/2019 | Merck Sharp & Dohme Corporation | MK-8591 (Drug) | Food and Beverage | In-kind items and services | $91.32 | General |
| Category: INFECTIOUS DISEASE | ||||||
About Dr. Craig Hendrix, M.D
Dr. Craig Hendrix, M.D is a Clinical Pharmacology healthcare provider based in Baltimore, Maryland. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 01/29/2007. The National Provider Identifier (NPI) number assigned to this provider is 1679619498.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Craig Hendrix, M.D has received a total of $53,651 in payments from pharmaceutical and medical device companies, with $7,550 received in 2021. These payments were reported across 59 transactions from 6 companies. The most common payment nature is "Consulting Fee" ($32,861).
Practice Information
- Specialty Clinical Pharmacology
- Location Baltimore, MD
- Active Since 01/29/2007
- Last Updated 07/08/2007
- Taxonomy Code 208U00000X
- Entity Type Individual
- NPI Number 1679619498
Products in Payments
- DELSTRIGO (Drug) $7,800
- MK-8591 (Drug) $409.58
- Viread (Drug) $109.42
- EDURANT (Drug) $47.52
- BOOSTRIX (Biological) $18.33
- BREO (Drug) $11.39
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.